300434.SZ
Sichuan Goldstone Asia Pharmaceutical, Inc.
SZSE · Industrials · C 制造业 · CN
CNY 11.27
−4.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.0B | 1.1B | 1.2B | 1.2B |
| Cost of Revenue | 434.4M | 433.2M | 469.2M | 467.7M | 480.5M |
| Gross Profit | 644.0M | 605.2M | 633.1M | 741.5M | 762.1M |
| Operating Expenses | |||||
| R&D Expense | 53.4M | 55.0M | 50.0M | 50.0M | 39.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 174.0M | 181.7M | 179.2M | 166.9M | 163.2M |
| Selling & Marketing Expense | 202.6M | 210.3M | 250.9M | 262.1M | 257.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 451.5M | 467.3M | 497.2M | 490.5M | 475.8M |
| Cost and Expenses | 885.9M | 900.4M | 966.5M | 958.2M | 956.3M |
| Operating Income (EBIT) | 209.5M | 153.5M | 130.5M | 177.9M | 292.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 208.9M | 152.8M | 122.7M | 177.0M | 290.5M |
| Income Tax Expense | 26.8M | 24.2M | 34.1M | 56.3M | 77.5M |
| Bottom Line | |||||
| Net Income | 184.8M | 131.6M | 91.8M | 126.2M | 218.8M |
| Earnings from Cont. Ops | 182.2M | 128.6M | 88.6M | 120.7M | 213.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 184.8M | 131.6M | 91.8M | 126.2M | 218.8M |
| Per Share | |||||
| Basic EPS | CN¥0.46 | CN¥0.33 | CN¥0.23 | CN¥0.31 | CN¥0.54 |
| Diluted EPS | CN¥0.46 | CN¥0.33 | CN¥0.23 | CN¥0.31 | CN¥0.54 |
| Revenue Per Share | CN¥2.68 | CN¥2.60 | CN¥2.76 | CN¥2.97 | CN¥3.07 |
| Shares | |||||
| Basic Shares Outstanding | 401.7M | 398.9M | 399.0M | 407.1M | 405.2M |
| Diluted Shares Outstanding | 401.7M | 398.9M | 399.0M | 407.1M | 405.2M |
| Profitability Metrics | |||||
| EBITDA | — | 257.2M | 235.4M | 273.8M | 386.4M |
| D&A | — | 103.7M | 105.0M | 95.9M | 94.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026